Finance

Beta
Lists
4523:TYO
Eisai Co Ltd
Â¥3,759.00
-1.55%
(-59.00) 1D
Jun 3, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4523...
Open
Â¥3,800
High
Â¥3,818
Low
Â¥3,719
Mkt. cap
1.10T
Avg. vol.
1.65M
Volume
2.18M
Dividend
4.26%
Quarterly dividend
Â¥40
Ex-dividend date
Sep 29, 2025
P/E ratio
27.48
52-wk high
Â¥5,349
52-wk low
Â¥3,719
EPS
Â¥137
Shares outstanding
286.43M
No. of employees
11K
Open
Â¥3,800
High
Â¥3,818
Low
Â¥3,719
Mkt. cap
1.10T
Avg. vol.
1.65M
Volume
2.18M
Dividend
4.26%
Quarterly dividend
Â¥40
Ex-dividend date
Sep 29, 2025
P/E ratio
27.48
52-wk high
Â¥5,349
52-wk low
Â¥3,719
EPS
Â¥137
Shares outstanding
286.43M
No. of employees
11K
Analyst outlook
Analyst Ratings
Based on 1 analyst giving stock ratings to 4523 in the past 3 months
Hold
Buy
0
Hold
1
Sell
0
12 month forecast
Based on 1 Wall Street analyst offering 12 month price targets for 4523 in the last 3 months.
Highest
Current ¥3,759.00
Â¥4,000.00 (+6.41%)
Average
Â¥4,000.32 (+6.42%)
Lowest
Â¥4,000.00 (+6.41%)
News stories
From sources across the web
Profile
Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices. Wikipedia
About Eisai Co Ltd
CEOHaruo Naito | Haruo Naito
Employees10.9K
FoundedDec 6, 1941
HeadquartersBunkyo City, Tokyo, Japan
SectorPharmaceutical industry
Websiteeisai.co.jp
Last report
May 15, 2026
Fiscal period
Q4 2026
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
205.43B / 195.68B
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
202.65B
197.36B
219.94B
205.43B
Cost of goods sold
42.60B
45.52B
51.08B
52.01B
Cost of revenue
42.60B
45.52B
51.08B
52.01B
Research and development expenses
38.79B
36.74B
39.20B
42.90B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
99.97B
104.06B
111.72B
112.04B
Operating expense
139.11B
138.36B
148.82B
155.20B
Total operating expenses
181.71B
183.88B
199.90B
207.21B
Operating income
20.94B
13.48B
20.03B
-1.78B
Other non operating income
1.00M
1.00M
-1.00M
-3.00M
EBT including unusual items
22.40B
14.53B
22.00B
-7.94B
EBT excluding unusual items
22.60B
14.34B
22.00B
591.00M
Income tax expense
7.07B
4.00B
4.16B
-4.75B
Effective tax rate
31.55%
27.51%
18.90%
59.77%
Other operating expenses
353.00M
-2.44B
-2.10B
250.00M
Net income
14.47B
10.16B
17.18B
-3.25B
Net profit margin
7.14%
5.15%
7.81%
-1.58%
Earnings per share
-
-
-
-
Interest and investment income
2.58B
2.30B
3.40B
3.92B
Interest expense
-916.00M
-1.44B
-1.43B
-1.55B
Net interest expenses
1.66B
856.00M
1.97B
2.38B
Depreciation and amortization charges
-
-
-
-
EBITDA
30.64B
23.29B
30.10B
8.20B
Gain or loss from assets sale
-
1.31B
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer